19.41  1.11 (6.07%)		12-11 16:00
Open: 18.43 High: 19.41 Volume: 74,904		Pre. Close: 18.3 Low: 18.16 Market Cap: 1,048(M)

Short term
Mid term
Targets	6-month :	26.28	1-year :	29.66
Resists	First :	22.5	Second :	25.39
Pivot price	20.64
Supports	First :	17.81	Second :	14.82
MAs	MA(5) :	18.96	MA(20) :	20.6
	MA(100) :	19.72	MA(250) :	21.75
MACD	MACD :	-0.8	Signal :	-0.5
%K %D	K(14,3) :	12	D(3) :	9.5
RSI	RSI(14): 43.8
52-week	High :	33	Low :	15.36

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PHVS ] has closed above bottom band by 32.6%. Bollinger Bands are 56.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	19.46 - 19.58	19.58 - 19.7
Low:	17.85 - 18.01	18.01 - 18.15
Close:	19.15 - 19.42	19.42 - 19.65

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Thu, 05 Dec 2024
Long Term Trading Analysis for (PHVS) - Stock Traders Daily

Mon, 25 Nov 2024
Pharvaris Reports Q3 2024 Progress and Financials - TipRanks

Mon, 25 Nov 2024
How To Trade (PHVS) - Stock Traders Daily

Thu, 14 Nov 2024
(PHVS) Long Term Investment Analysis - Stock Traders Daily

Wed, 13 Nov 2024
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan

Mon, 11 Nov 2024
PHVS Makes Notable Cross Below Critical Moving Average - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	54 (M)
Shares Float	19 (M)
Held by Insiders	9.4 (%)
Held by Institutions	87.5 (%)
Shares Short	137 (K)
Shares Short P.Month	813 (K)

EPS	-2.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-26.8 %
Return on Equity (ttm)	-45.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.15
Qtrly Earnings Growth	0 %
Operating Cash Flow	-99 (M)
Levered Free Cash Flow	-55 (M)

PE Ratio	-7.06
PEG Ratio	0
Price to Book value	2.64
Price to Sales	0
Price to Cash Flow	-10.61

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.